France Approved IV Ketamine for Suicidal Crisis. The FDA Should Be Uncomfortable Right Now.

Picture an emergency psychiatrist in Lyon in April 2026, reaching for an IV line instead of a phone to a crisis team. She has a patient in acute suicidal crisis — not ideation, not elevated risk on a PHQ-9, but imminent, actionable intent. She now has a regulatory framework to support what she does next. In March 2026, France’s Agence nationale de sécurité du médicament et des produits de santé issued the first national authorization anywhere in the world for intravenous racemic ketamine specifically indicated for the treatment of adult severe suicidal crisis. That authorization, reported in a correspondence published in The Lancet, is not a pilot program or a compassionate use carve-out. It is a full national approval — first of its kind, globally.

Most of the commentary will focus on what France got right. The more important question is what this exposes about what everyone else has gotten wrong.

The Lancet correspondence is explicit on one structural point: there is currently no officially approved, evidence-based, rapid-acting pharmacological treatment for imminent suicide risk anywhere in the world — not in the EU, not in the UK, and not in the United States. The FDA approved esketamine nasal spray under the brand name Spravato in 2019 for treatment-resistant depression and, separately, for major depressive disorder with acute suicidal ideation or behavior. But Spravato’s suicidality indication is bounded by a REMS program so operationally constrictive that it functions, in practice, as a specialty access program rather than an emergency intervention. You cannot administer it in a general ED. You cannot push it IV. The molecule and the delivery system together define the clinical envelope — and that envelope does not cover the acute psychiatric emergency that a suicidal crisis actually is.

The Delivery System Is the Drug

This is the counterintuitive insight that France’s approval forces into view. The conventional assumption in psychiatric drug development is that the active molecule is the intervention — that esketamine and racemic ketamine are, at their core, the same therapeutic story told in different formulations. By that logic, Spravato’s 2019 approval should have functionally solved the regulatory gap for ketamine-based crisis intervention. It did not, and the reason is operational rather than pharmacological.

Racemic ketamine — the mixture of R- and S-enantiomers that has been used off-label in emergency psychiatry for years — is administered intravenously. The IV route produces a rapid, titratable, dose-controlled intervention that fits inside the workflow of an emergency department or acute inpatient unit. Spravato, as an intranasal S-ketamine formulation, requires a certified healthcare setting, mandatory two-hour post-dose monitoring, and a restricted distribution framework under the FDA’s REMS. According to the FDA’s own Spravato prescribing information, the drug cannot be dispensed directly to patients for home or unsupervised use — a constraint that, while appropriate for outpatient depression management, renders it structurally incompatible with emergency psychiatric care. The French authorization, by contrast, is built around the IV racemic formulation precisely because the clinical context demands immediate, monitored, titratable intervention in a setting — the emergency department or acute psychiatric unit — where IV access is already the standard of care.

Which raises an uncomfortable question for the FDA: if the agency approved a ketamine-derived molecule for suicidal ideation in 2019 and the clinical gap the French just addressed in 2026 still exists, what exactly did that approval accomplish for the highest-acuity patients?

The evidence base underlying France’s decision draws on a body of controlled trial data that has been accumulating for over a decade. The KETACRISIS trial — a randomized controlled study conducted in France examining IV racemic ketamine against midazolam in adults presenting with acute suicidal crisis — demonstrated significant anti-suicidal effects at 24 hours post-infusion. That trial was not a surrogate-endpoint exercise. It enrolled patients in genuine psychiatric emergency, used a clinically validated active comparator, and measured outcomes that mattered at the moment of highest risk. This is the evidentiary architecture that supported the French authorization, and it is precisely the architecture the FDA’s current approval pathways struggle to accommodate.

Why FDA Pathways Weren’t Built for This Emergency

The structural problem is not that the FDA lacks expedited tools. Breakthrough Therapy Designation, Fast Track, Accelerated Approval, Priority Review — the agency’s guidance on expedited programs describes these as mechanisms to get important therapies to patients faster. The problem is that all of these pathways were designed with a clinical model in mind that assumes a defined patient population, a stable disease state, and an endpoint that can be measured over weeks or months. Acute suicidal crisis violates all three assumptions simultaneously.

Consider what a Phase 3 trial design for this indication actually requires. You need to enroll patients who are, by clinical definition, in immediate danger. Your randomization window is measured in hours. Your primary endpoint — reduction in suicidal crisis severity — must be assessed within 24 to 72 hours of dosing, because that is when the intervention either works or doesn’t. Your control arm raises immediate ethical questions about withholding treatment from a suicidal patient. And your safety monitoring infrastructure must be capable of detecting adverse events in a population where the adverse event of concern — a suicide attempt — is also the disease state you are treating. I’ve designed protocols for high-risk psychiatric populations, and the IRB conversation alone for an acute suicidality trial can take longer than enrollment opens for a standard Phase 2 oncology study.

The FDA’s guidance on clinical trial design in serious psychiatric conditions acknowledges many of these challenges in general terms but stops short of providing the operational specificity that sponsors need to actually run these trials. The agency’s 2023 guidance on trial enrichment strategies and its broader framework for evidence generation in CNS conditions address population selection and endpoint validation — but neither document resolves the fundamental ethics-versus-evidence tension that has kept acute suicidality underserved as an indication for thirty years.

France moved. The ANSM looked at the KETACRISIS data, weighed it against the absence of any approved alternative, and made a regulatory risk-benefit call that the FDA has not made. One authorization does not constitute a global evidence consensus — but it does constitute a precedent, and precedents in regulatory science travel.

The Post-Approval Problem No One Is Talking About Yet

Approval, in this indication, is the beginning of the monitoring challenge rather than the end of it. IV racemic ketamine carries a known dissociative and hemodynamic risk profile. In an emergency psychiatric setting, where patients may be agitated, medically comorbid, or co-intoxicated, the margin for administration error is narrow. France’s authorization almost certainly includes specific conditions of use, mandatory setting requirements, and pharmacovigilance obligations — the Lancet correspondence notes the authorization’s role in recognizing ketamine’s “clinical potential” within a structured national framework. But the post-marketing signal detection challenge for a drug used in acute psychiatric emergency is categorically different from standard pharmacovigilance. Adverse events in this population are difficult to attribute causally. Underreporting in emergency settings is endemic. And the counterfactual — what would have happened to this patient without the intervention — is, by definition, unknowable.

The FDA’s post-market safety framework for Spravato offers one reference model: mandatory patient monitoring, REMS-based reporting, and periodic safety update reviews. But Spravato’s REMS was designed around a controlled outpatient setting. A post-approval safety architecture for IV ketamine in acute psychiatric emergency would need to function inside the operational reality of an ED that is simultaneously managing a trauma bay, a sepsis workup, and a psychiatric hold. That is a materially different monitoring environment, and no existing FDA guidance on REMS design or post-market surveillance in psychiatric indications was written with it in mind.

The EMA, meanwhile, has not issued a parallel authorization, and the European regulatory picture for IV racemic ketamine in this indication remains fragmented across member states that have been managing off-label use under their own national frameworks. France’s ANSM authorization changes that landscape — it creates a reference document that other national authorities within the EU can evaluate, debate, or challenge. The FDA has no equivalent reference point to benchmark against, because the agency that is closest in regulatory philosophy and data standards to the FDA just moved first.

Here is what the next 24 months will tell us: whether any U.S. sponsor has the appetite to construct a Phase 3 development program for IV racemic ketamine in acute suicidal crisis using the KETACRISIS trial as its foundational evidence package, and whether the FDA has the interpretive flexibility to treat a French national authorization as meaningful external evidence under its real-world evidence framework. The agency’s guidance on using foreign clinical data to support U.S. applications exists. The question is whether the institutional will to apply it to a high-acuity psychiatric emergency — where the cost of regulatory inaction is measured in lives per year — will arrive before another decade of off-label use fills the gap that no one in the regulatory system has officially acknowledged it has the authority to close.

References

1. The Lancet — “[Correspondence] Suicidal crisis: first regulatory approval of IV racemic ketamine” (2026)
2. FDA Prescribing Information — Spravato (esketamine) nasal spray, including REMS program requirements (2019, updated)
3. FDA Guidance — Expedited Programs for Serious Conditions — Drugs and Biologics (2014)
4. FDA Guidance — Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products (2023 update)
5. FDA Guidance — Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products (2020)
6. Agence nationale de sécurité du médicament et des produits de santé (ANSM) — National authorization for intravenous racemic ketamine in adult severe suicidal crisis (March 2026)